Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status.
Abeykoon JP, Rech KL, Young JR, Ravindran A, Ruan GJ, Dasari S, Morlote DM, King RL, Rummage C, Zanwar S, Acosta-Medina AM, Tobin WO, Shah MV, Bennani NN, Vassallo R, Ryu JH, Koster MJ, Davidge-Pitts CJ, Witzig TE, Goyal G, Go RS; Mayo Clinic–University of Alabama at Birmingham Histiocytosis Working Group.
Abeykoon JP, et al. Among authors: shah mv.
JAMA Oncol. 2022 Dec 1;8(12):1816-1820. doi: 10.1001/jamaoncol.2022.4432.
JAMA Oncol. 2022.
PMID: 36201194
Free PMC article.